1<!DOCTYPE html>
2
3Anonymous
4/bestp
5/bestp/domrep.nsf
6BD16ACCCEA69561D002587830069C473
8
9
10
11
12
13
140
15
16
17/bestp/domrep.nsf/products/db-how-pharma-utilizing-social-media-for-delivering-medical-education?opendocument
18
19opendocument
2044.222.134.250
21
22
23www.best-in-class.com
24/bestp/domrep.nsf
25DB




» Products & Services » » Medical Affairs » Medical Education

How Pharma is Utilizing Social Media for Delivering Medical Education

ID: 5705


Features:

18 Info Graphics

10 Data Graphics

100+ Metrics

11 Narratives


Pages/Slides: 34


Published: 2021


Delivery Format: Online PDF Document


 

License Options:


Buy Now

 


  • STUDY OVERVIEW
  • BENCHMARK CLASS
  • SPECIAL OFFER
Non-members: Click here to review a complimentary excerpt from “How Pharma is Utilizing Social Media for Delivering Medical Education”

STUDY OVERVIEW

The pandemic pushed pharma to pivot medical education programs from live meetings to virtual meetings and other platforms such as social media. This study examines how pharma is adjusting its medical education programs for the future.

Best Practices, LLC conducted this study to highlight current trends and future directions for pharma utilizing social platforms for HCP education, in particular public and closed social media platforms. The study also presents the traits of effective public and closed social media platforms and hurdles to social media utilization


Data segmented by respondent’s geographical responsibility – US vs. Global + US vs. Global ex-US

KEY TOPICS

  • Utilization and Effectiveness of Public and Closed Social Media Platforms
  • Traits of Effective Public and Closed Social Media Platforms
  • Hurdles to Social Media Utilization

SAMPLE KEY METRICS
  • Support to HCP accredited medical education programs on public and closed social media platforms – Total benchmark class
  • Interview narratives around Medical’s involvement in social media
  • Most utilized and effective social media platforms for medical education programs, Traits of an effective social media platform
  • Interview narrative around key considerations when gearing up to begin using social media
  • Trend around tweetorials and interview narrative around acceleration of technology platforms due to the pandemic
  • Interview narratives around success stories with social media and medical education
  • Public social media platform utilization and effectiveness
  • Interview narrative around hurdles faced by Medical Affairs while utilizing public platforms
  • Navigating social media use and RWE generation
  • Closed social media platform utilization and effectiveness
  • Challenges to utilizing social media for supporting medical education programs
  • Characteristics of an effective social media platform
  • Biggest drawbacks / impediments to utilizing social media platforms for medical education programs
  • Interview narratives around impediments to using social media platforms
  • Interview narrative around most crucial compliance issues associated with social media

SAMPLE KEY FINDING

  • Create a blueprint for using social media for medical education: Work with regulatory and legal to draft a compliance road map for using social media for HCP education. With the next gen HCPs Internet savvy, organizations not using social media for education will lose credibility.

METHODOLOGY

This study engaged 32 leaders from 27 biopharmaceutical companies via a benchmark survey; deep-dive interviews were conducted with selected study participants to provide further insight

Industries Profiled:
Pharmaceutical; Health Care; Manufacturing; Biotech; Consumer Products; Diagnostic; Medical Device; Consulting; Biopharmaceutical


Companies Profiled:
AbbVie; Merck; Astellas; Merck Serono; Bayer; Eisai; Teva Pharmaceutical Industries Ltd; Roche; GlaxoSmithKline ; AstraZeneca; Biogen; bioMerieux; Allergan; Sanofi Genzyme; Otsuka Pharmaceutical Development & Commercialization; Inc. (OPDC); Sandoz; Baxter BioScience; Ipsen; Merz Pharma; MEDiSTRAVA; Kyowa Kirin; CSL Behring; Grunethal; GRAIL; Apellis Pharmaceuticals; Rhythm Pharmaceuticals; Taiho Pharma

If you purchase Best Practice Database document(s), you will have 30 days from the date of purchase to apply some or all of the cost of the document(s) toward the cost of a Full Access Individual, Pharma, Group or University Membership. Write us at DatabaseTeam@bestpracticesllc.com or call David Guinn at 919-767-9179 if you have any questions.